Keyword: Black Diamond Therapeutics
Last year, we asked: Are too many early-stage biotechs going for IPOs, and when will the bubble burst?
The public markets have been receptive to early-stage biotechs but will the IPO remain open? We asked our Fierce 15 winners what they thought.
Alexion replaces CFO Clancy in possible M&A push; Black Diamond nabs three new R&D execs; X4 Pharma founder Skerlj takes on R&D head duties.
After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up its research work.
Versant Ventures launched Black Diamond in December 2018 with $20 million to go after an overlooked group of oncogenes, or mutated forms of genes that can drive cancer. A month later, the company picked up another $85 million to move its lead program into the clinic in early 2020.